Table 1 Patient demographics by etiology (N = 288).

From: Impact of underlying liver disease on unresectable hepatocellular carcinoma treated with immune checkpoint inhibitors

 

All patients (%)

Viral (%)

Non-viral (%)

P value

N

288

206 (71.9)

82 (28.5)

 

Age (years), median

64

63.5

68

<0.001*

Male

245 (85.1)

172 (83.5)

73 (89.0)

0.27

Cirrhotic

250 (86.8)

188 (91.3)

62 (75.6)

<0.001*

Diabetic

96 (33.3)

54 (26.2)

42 (51.2)

<0.001*

Etiology:

HBV

56 (19.4)

56 (27.2)

N/A

 

HCV

151 (52.4)

151 (73.3)

N/A

EtOH

75 (26.0)

42 (20.4)

33 (40.2)

NASH

45 (15.6)

8 (3.9)

37 (45.1)

Other

16 (5.6)

14 (6.8)

2 (2.4)

None

17 (5.9)

N/A

17 (20.7)

Measurable Viral Load

 

52 (25.2)

N/A

 

Child Pugh:

A

195 (67.7)

148 (71.8)

47 (57.3)

0.025*

B

93 (32.3)

58 (28.2)

35 (42.7)

Extrahepatic Metastasis

105 (36.5)

75 (36.4)

30 (36.6)

1

Portal Vein Tumor Thrombus

128 (44.4)

101 (49.0)

27 (32.9)

0.018*

Baseline AFP ≥ 400 ng/mL

120 (41.7)

89 (43.2)

31 (37.8)

0.43

BCLC:

A

4 (1.4)

3 (1.5)

1 (1.2)

0.007*

B

74 (25.7)

42 (20.4)

32 (39.0)

C

210 (72.9)

161 (78.2)

49 (59.8)

ECOG PS:

0

209 (72.6)

152 (73.8)

57 (69.5)

0.21

1

70 (24.3)

50 (24.3)

20 (24.4)

2

9 (3.1)

4 (1.9)

5 (6.1)

ICI:

Atezolizumab

47 (16.3)

36 (17.5)

11 (13.4)

0.48

 

Nivolumab

223 (77.4)

155 (75.2)

68 (82.9)

0.86

 

Pembrolizumab

18 (6.3)

15 (7.3)

3 (3.7)

0.30

ICI Monotherapy

173 (60.1)

119 (57.8)

54 (65.9)

0.23

ICI + Antiangiogenic Agent

113 (39.2)

85 (41.3)

28 (34.1)

0.29

Dual ICI (Nivolumab + Ipilimumab)

2 (0.7)

2 (1.0)

0 (0.0)

1

Prior Resection

58 (20.1)

45 (21.8)

13 (15.9)

0.33

Prior LRT (incl. SBRT)

171 (59.4)

128 (62.1)

43 (52.4)

0.14

Concurrent LRT (incl. SBRT)

126 (43.8)

92 (44.6)

34 (41.5)

0.69

Post-ICI therapy:

63 (21.9)

49 (23.8)

14 (17.1)

0.27

 

Lenvatinib

30 (47.6)

25 (51.0)

5 (35.7)

 
 

Sorafenib

12 (19.0)

8 (16.3)

4 (28.6)

 
 

Ramucirumab

8 (12.7)

7 (14.3)

1 (7.1)

 
 

Bevacizumab only

9 (14.3)

6 (12.2)

3 (21.4)

 
 

Regorafenib

2 (3.2)

2 (4.1)

0 (0.0)

 
 

Cabozantinib

2 (3.2)

1 (2.0)

1 (7.1)

 
  1. *Statistically significant (P value < 0.05).
  2. HBV hepatitis B virus, HCV hepatitis C virus, EtOH alcohol use, NASH non-alcoholic steatohepatitis, AFP alpha fetoprotein, BCLC Barcelona Clinic Liver Cancer, ECOG Eastern Cooperative Oncology Group, PS performance status, ICI immune checkpoint inhibitor, LRT locoregional therapy, SBRT stereotactic body radiation therapy.
Back to article page